Cleveland Clinic researchers found that a specific gut microbe enzyme, CutC, contributes to increased stroke severity. Targeting this enzyme may prevent stroke and improve post-stroke outcomes through dietary interventions and transplantation of beneficial gut microbes.
A new study identified mechanisms by which COVID-19 can lead to Alzheimer's disease-like dementia. Researchers found close network relationships between SARS-CoV-2 and genes/proteins associated with several neurological diseases, including Alzheimer's.
Researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. Inhibiting the protein H6PD leads to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer.
Researchers found that a Western diet high in fat and sugar impairs intestinal immune cell function in mice, leading to increased gut permeability and chronic inflammation. Switching to a standard diet reverses the impairment.
The new system automates the organ donation process for hospital staff, saving time and improving patient care. The collaboration enables the referral of potential donors directly to the OPO without manual calls, enhancing the efficiency of the entire process.
A team of scientists tracked SARS-CoV-2 mutations in Northeast Ohio and found that newer variants were associated with lower hospitalizations and deaths. The study provides insight into how viral clades can impact patient outcomes.
Researchers at Cleveland Clinic Florida have identified a novel mechanism that leads to MDA5 activation during virus infection, and found that inhibiting the PLpro enzyme may help strengthen the human immune response against SARS-CoV-2. This could potentially lead to new anti-COVID-19 therapeutics targeting the PLpro enzyme.
Researchers found a type of yeast called Debaryomyces hansenii elevated in areas of unhealed wounds in Crohn's disease patients. The study suggests targeting this infection may be a viable approach to treat or prevent the disease, and further studies are needed.
A promising new COVID-19 vaccine candidate utilizing nanotechnology has shown strong efficacy in preclinical disease models, producing potent neutralizing antibodies and preventing infection and disease symptoms. The vaccine candidate may also be thermostable, easing shipping and storage constraints.
A Cleveland Clinic-led team developed a platform, My Personal Mutanome (MPM), to analyze genetic mutations and their responses to drugs in cancer. The platform integrates clinical data, protein-protein interactions, and functional sites to identify actionable mutations for personalized medicine.
A new five-year study tests the effect of home-based indoor cycling on slowing Alzheimer's disease progression in healthy older individuals at high genetic risk. The study aims to enroll 150 participants and assess the impact of high-intensity interval training on brain regions critical to memory function.
A new study published in Nature Microbiology reveals how Zika virus causes brain calcification, a common birth defect associated with prenatal infection. The research team identified the proteins BMP2 and NS3 as central players in the development of calcifications, suggesting novel strategies to prevent this birth defect.
The Cleveland Clinic has received two grants totaling $4.6 million to investigate the therapeutic potential of lenalidomide in early-stage Alzheimer's disease. The studies aim to determine if lenalidomide safely reduces inflammatory biomarkers and improves cognition in patients with mild cognitive impairment.
Researchers developed a novel, patient-derived model of ulcerative colitis to identify promising targets for new treatments. The model showed that inhibiting CXCL8 expression slowed disease progression.
Researchers at Cleveland Clinic's Taussig Cancer Institute have identified a potential new class of targeted drugs to treat myeloid leukemias, including those with the common TET2 gene mutation. The new pharmacological strategy, TETi76, preferentially targets and eliminates leukemia cells with TET2 mutations in preclinical models.
Researchers from Cleveland Clinic note that COVID-19 can affect the central nervous system, causing disorders such as ischemic stroke, encephalitis, and epileptic seizures. The virus enters the brain through the blood-brain barrier or nasal cavity, triggering a cytokine storm that leads to inflammation and damage.
A Cleveland Clinic study shows that bariatric surgery prior to contracting COVID-19 is associated with a lower risk of hospital and ICU admission. Patients who underwent weight-loss surgery had a significantly lower rate of severe illness compared to those without a history of bariatric surgery.
The Cleveland Clinic has successfully used a recent FDA-approved ablation technology to treat patients with large liver tumors. The minimally invasive procedure involves inserting a microwave needle into the tumor and delivering heat to destroy it, resulting in better postoperative recovery and reduced risk of complications.
A global clinical trial led by Cleveland Clinic found that rilonacept resolved acute pericarditis episodes and reduced recurrence risk. The study showed 81% of patients on rilonacept reported no symptoms, compared to 25% on placebo.
Researchers have found that melatonin may be a viable treatment option for COVID-19, reducing the likelihood of testing positive by nearly 30%. The study analyzed patient data from Cleveland Clinic's registry and identified 34 potential repurposing candidates, including melatonin.
Researchers aim to create a low-cost, time-efficient procedure to identify and screen patients at high risk of cognitive decline. A new risk calculator and screening tool will be developed and validated to detect reversible causes of cognitive decline.
Researchers analyzed 1,330 disease-associated genes and identified 18 features associated with pathogenic variants and 14 with benign variants. The study provides a molecular atlas of pathogenic mutations and aims to accelerate personalized drug discovery and precision medicine.
Researchers will investigate chromatin organization within cells and how it changes over time to identify disease targets. The study aims to develop navigable maps of chromatin architecture across multiple cell types, enabling new treatments for a range of diseases.
A Cleveland Clinic researcher has been awarded a grant to identify biomarkers for predicting dementia in patients with Parkinson's disease. The five-year project aims to develop a predictive model using imaging, blood, and genetics data to identify individuals at risk of developing dementia as their disease progresses.
A study by Cleveland Clinic found that surgically induced weight loss of 5-10% improves life expectancy and cardiovascular health. The research suggests metabolic surgery may contribute to health benefits independent of weight loss.
A new Cleveland Clinic study of over 13,000 patients found no link between influenza vaccination and COVID-19 risk. The researchers strongly advise people to get their flu vaccines this fall to mitigate the risk of simultaneous viral infections and epidemics.
A $10.4 million NIH grant will explore the molecular level differences in glioblastoma incidence, survival, and treatments between males and females. Researchers aim to gain a better understanding of sex differences in tumor growth, diagnosis, and treatment for more personalized therapies.
Researchers adapted principles of quantum control to calculate alternative interventions for infection and cancer. They developed a mathematical algorithm that can design and speed up specific interventions to prevent or overturn drug resistance, offering a promising approach to defeating drug-resistant diseases.
Researchers developed a nomogram that predicts COVID-19 hospitalization risk based on symptoms, medication use, and demographic factors. The model offers substantially better predictions than using no model at all, providing valuable insights for personalized care and resource allocation.
A recent Cleveland Clinic study has identified genetic factors that may influence an individual's susceptibility to COVID-19. The research found associations between polymorphisms in the ACE2 and TMPRSS2 genes and increased risk of cardiovascular and pulmonary conditions, as well as poor outcomes with COVID-19.
Cleveland Clinic researchers found a significant increase in patients with stress cardiomyopathy, also known as broken heart syndrome, during the COVID-19 pandemic. Symptoms include chest pain, shortness of breath, and irregular heartbeat.
The two institutions will recruit underrepresented minority PhD students into their biomedical research programs, building a pipeline of minority scientists in the Cleveland area. The grant aims to increase diversity and inclusion in STEM fields, promoting creativity, problem-solving, and innovation.
A Cleveland Clinic-led research team will study the central vein sign as a reliable diagnostic marker for MS, aiming to improve accuracy and simplify clinical decision-making. The prospective study will enroll 400 patients at 11 centers in North America.
Researchers identified WWP1 mutations as a genetic driver of PTEN hamartoma tumor syndrome-associated cancer. The study found that WWP1 variants lead to abnormal activation of the enzyme inhibiting PTEN function and contributing to cancer development, suggesting a new therapeutic target.
A new Cleveland Clinic study evaluates germline genomic profiles in C-AYA patients with solid tumors, revealing a significant proportion carry heritable cancer-predisposing gene variants. The research highlights the need for genetics evaluation and genetic testing to inform management and treatment options.
Researchers have identified phenylacetylglutamine (PAG), a gut microbe byproduct produced from phenylalanine breakdown, as a risk factor for cardiovascular disease. Elevated PAG levels predict adverse cardiac events and are associated with enhanced platelet reactivity and clotting potential.
Researchers found a genetic variant associated with aggressive disease and shorter survival in men with metastatic prostate cancer. Genetic testing for the HSD3B1(1245C) variant may help identify patients most likely to benefit from additional treatment.
Researchers found CNVs to be genomic modifiers of ASD/DD risk in individuals with PHTS, providing insight into the disorder's clinical outcomes and potential predictors for medical management. The study suggests CNV burden analysis may aid in predicting clinical outcomes for other clinically heterogeneous disorders.
A new study has identified a genetic anomaly associated with poor response to glucocorticoid asthma treatment. The research found that patients with the HSD3B1(1245A) variant are less likely to respond to treatment and may develop severe asthma.
Researchers found that using lungs from donors considered high risk for certain infectious diseases results in similar one-year survival rates for recipients. The study suggests broadening the definition of 'increased risk' donors could increase overall organ utilization and reduce deaths on the waitlist.
Researchers aim to understand how ecological and evolutionary mechanisms contribute to lung cancer development and progression, potentially leading to new treatment options. The team will investigate patterns in drug sensitivity and resistance to identify molecular hallmarks that predict treatment changes.
Researchers found that low lymphocyte levels are associated with increased mortality from heart disease, cancer, and respiratory infections. The study suggests using pragmatic immune status indicators to identify patients at highest risk for mortality.
Researchers led by Dr. Stanley Hazen will explore how gut microbes convert digested nutrients into chemical signals, affecting cardiovascular and metabolic diseases. The team aims to identify specific microbial pathways linked to atherosclerosis, thrombosis, and obesity.
Cleveland Clinic researchers have identified a novel target for anti-fibrotic therapies: the TRPV4-PI3Kγ complex. This complex amplifies TGF-β signaling to generate myofibroblasts, which produce and contract extracellular matrix to form scar tissue. The study offers promising support for new treatment approaches.
A new calculator developed by Cleveland Clinic researchers can estimate a patient's risk of developing major health complications over the next 10 years depending on their treatment choice. The calculator provides personalized evidence-based information on heart disease, stroke, and other risks with usual care versus surgical treatment.
A two-year study by Cleveland Clinic researchers found that patients treated with functional medicine experienced significant improvements in health-related quality of life. Compared to those seen in primary care, these patients showed larger and more sustainable benefits in their physical health.
A new study developed genetic-based epilepsy risk scores that can accurately distinguish between healthy patients and those with epilepsy, as well as between patients with generalized and focal epilepsies. These scores have the potential to identify high-risk patients earlier and guide precision treatment.
Researchers at Cleveland Clinic identified a metabolite associated with specific PTEN mutations, distinguishing those at high risk for neurodevelopmental disorders from cancer. The findings may help tailor treatments to individual patients with germline PTEN mutations.
A study published by Cleveland Clinic shows that weight-loss surgery is associated with a lower risk of death and major adverse cardiovascular events than usual medical care. Patients who underwent surgery also had better diabetes control, used fewer medications, and lost more weight.
Researchers at Cleveland Clinic have identified FGF2 as a novel druggable target for glioblastoma, the most common primary malignant brain tumor. The study reveals that FGF2 is an intermediary in a multi-step pro-cancer signaling loop, suggesting that targeting it may halt the growth and spread of glioblastoma.